Novo Nordisk A/S reported on January 20, 2025, about its ongoing share repurchase program which started on November 11, 2024, aiming to buy back B shares worth up to DKK 20 billion over 12 months. As of January 17, 2025, the company had repurchased 23,691,366 B shares at an average price of DKK 816.17, with total transactions reaching DKK 19.34 billion.